Riskpilot← Back to searchSign inGet full accessZerion Pharma A/S
A/SActiveCVR 40169229Fruebjergvej 3Manufacture of pharmaceutical preparations · NACE 2120Est. 201911 employeeswww.zerion.eu
Revenue 2024
DKK 3,5M
-3% vs 2023
EBITDA margin
-368.8%
-12% vs 2023
Equity ratio
-23.4%
Financial strength
Net profit 2024
DKK -220K
+98% vs 2023
| Revenue | DKK 3,5M | -3% |
| EBITDA | DKK -12,7M | -12% |
| Net profit | DKK -220K | +98% |
| Total assets | DKK 9,7M | +14% |
| Equity | DKK -2,3M | +84% |
| Employees | 11 | — |
Legal name
Zerion Pharma A/S
CVR number
40169229
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
14. januar 2019
Share capital
DKK 1.076.938
Employees
11 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand eller næstformand i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed med udvikling af lægemidler samt enhver i forbindelse hermed stående virksomhed.
Address
Fruebjergvej 3
Phone
+4540968018
Email
jdh@zerion.eu
Website
www.zerion.eu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -1.068 | 784 | 1.933 | 3.273 | 3.560 | 3.452 |
| Staff expenses | -279 | -1.993 | -6.245 | -9.538 | -6.157 | -6.897 |
| EBITDA | -1.347 | -3.739 | -12.960 | -20.451 | -11.410 | -12.731 |
| Depreciation & amort. | -0 | -1 | -220 | -441 | -537 | -537 |
| EBIT | -1.347 | -3.740 | -13.180 | -20.892 | -11.947 | -13.268 |
| Net financials | 0 | -271 | -566 | -1.237 | -1.558 | 10.768 |
| Profit before tax | -754 | -4.011 | -13.746 | -22.129 | -13.506 | -2.500 |
| Tax | 296 | -534 | -2.612 | -3.272 | -2.404 | -2.280 |
| Net profit | -1.051 | -3.478 | -11.134 | -18.857 | -11.102 | -220 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 1.035 | 7.000 | 13.698 | 12.423 | 8.472 | 9.671 |
| Equity | 31 | -1.029 | -867 | -9.958 | -13.731 | -2.258 |
| Long-term debt | 0 | 6.374 | 10.579 | 17.949 | 19.384 | 8.245 |
| Short-term debt | 1.003 | 1.655 | 3.985 | 4.432 | 2.819 | 3.684 |
| Total debt | 1.003 | 8.029 | 14.564 | 22.381 | 22.203 | 11.930 |
EBITDA margin
-368.8%
This company
15.8%
Market median
-2434% vs market
20192024
Equity ratio
-23.4%
This company
38.2%
Market median
-161% vs market
20192024
Return on equity
-22002000.0%
This company
18.4%
Market median
-119576187% vs market
20192024
Net profit margin
-6.4%
This company
8.1%
Market median
-179% vs market
20192024
Asset turnover
0.36×
This company
1.12×
Market median
-68% vs market
20192024
Debt / equity
5.28×
This company
0.62×
Market median
-752% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-14 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
OS Management | Management | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2024 | — | — | |
| Deputy Chairman | 2021 | — | — | |
| Board of Directors | 2019 | — | — | |
| Deputy Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 5.0% | 5.0% | 2025 | |
Running Man ApS | Company | 5.0% | 5.0% | 2019 |
Bohring ApS | Company | 5.0% | 5.0% | 2019 |
Waterman ApS | Company | 5.0% | 5.0% | 2019 |
Mohan.dk ApS | Company | 5.0% | 5.0% | 2019 |
WIBORG INTERNATIONAL HOLDING ApS | Company | 5.0% | 5.0% | 2019 |
CBFR ApS | Company | 5.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
WIBORG INTERNATIONAL HOLDING ApS
Zerion Pharma A/S Board members of Zerion Pharma A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ole Sylvester-Hvid Wiborg | Management | 0 companies |
| Dorte Juhl Arnbjerg | Board of Directors | 0 companies |
| Adam Jun Bohr | Board of Directors | 0 companies |
| Carl-Åke Carlsson | Chairman | 0 companies |
| Christian Bone Falk-Rønne | Board of Directors | 0 companies |
| Torsten Rüdiger Goesch | Chairman | 0 companies |
| Peter Mohan Christiansen | Chairman | 0 companies |
| Allan Stich | Board of Directors | 0 companies |
| Lars Lykke Thomsen | Deputy Chairman | 0 companies |
| Jorrit Jeroen Water | Board of Directors | 0 companies |
| Korbinian Arthur Maria Löbmann | Deputy Chairman | 0 companies |